- John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science, Massachusetts Institute of Technology
- Director, Laboratory for Multiscale Regenerative Technologies
- Director, Marble Center for Cancer Nanomedicine, Koch Institute
- Investigator, Howard Hughes Medical Institute
Dr. Bhatia trained at Brown, MIT, Harvard, and MGH. She was a faculty member of the Bioengineering Department at University of California at San Diego for 6 years. She and her 150+ trainees (29 graduate, 25 postgraduate, 100+ undergraduate) have published more than 160 manuscripts that have collectively accumulated over 16,000 citations. She is the co-founder of two biotechnology startup companies, holds over 40 issued or pending patents in tissue engineering, biomedical microsystems, and nanobiotechnology and has worked in industry at Pfizer, Genetics Institute, ICI Pharmaceuticals, and Organogenesis. She co-authored the first undergraduate text on tissue engineering, as well a white paper about ‘convergence’ in life, physical and engineering sciences, highlighting the need for cooperation amongst research, economic and policy experts to advance biomedicine and healthcare. She is a frequent advisor to governmental organizations on nanobiotechnology, biomedical microsystems, and tissue engineering.
Dr. Bhatia is an elected member of the National Academy of Engineering, the American Academy of Arts & Sciences, and a fellow of the Massachusetts Academy of Sciences, Biomedical Engineering Society, American Institute for Medical and Biological Engineering, and American Society for Clinical Investigation. She has been awarded the 2014 Lemelson-MIT Prize; the 20th Heinz Award for Technology, the Economy, and Employment; the David and Lucile Packard Fellowship given to “the nation’s most promising young professors in science and engineering;” the NSF CAREER Award; the Y.C. Fung Young Investigator Award of the American Society of Mechanical Engineers; the Young Investigator Award of the American College of Clinical Pharmacology; the Brown Engineering Alumni Medal; and was named a Merkin Fellow of the Broad Institute. Her work has been profiled broadly, such as in Scientific American and Popular Science, the Boston Globe, Popular Science, Forbes, PBS’s NOVA scienceNOW, the Economist, and MSNBC.
- MD, Harvard Medical School, 1999
- Ph.D in Biomedical Engineering, Massachusetts Institute of Technology, 1997
- M.S. in Mechanical Engineering, Massachusetts Institute of Technology
- B.S. in Biomedical Engineering, Brown University
- National Academy of Sciences, 2017
- National Academy of Inventors, 2015
- Heinz Award, 2015
- National Academy of Engineering, 2015
- Lemelson-MIT Prize, 2014
- Massachusetts Academy of Sciences
- Biomedical Engineering Society
- American Institute for Medical and Biological Engineering
- American Society for Clinical Investigation
- David and Lucile Packard Fellowship
- NSF Career Award
- Y.C. Fung Young Investigator Award of the American College of Clinical Pharmacology
- Brown Engineering Alumni Medal
- Merkin Fellow, Broad Institute
- Harvard Medical School Diversity Award
- Harvard-MIT Thomas McMahon Mentoring Award
Our laboratory conducts research at the intersection of engineering, medicine, and biology to develop novel platforms for understanding, diagnosing, and treating human disease. Our long-term goals are to improve cellular therapies for liver disease, develop microtechnology tools to systematically study living cells, and design multifunctional nanomaterial systems which assemble and communicate to interrogate and coordinately treat cancer. We have developed technologies for interfacing living cells with synthetic systems, enabling new applications in tissue regeneration, stem cell differentiation, medical diagnostics and drug delivery. One such platform applies microfabrication technologies used in semiconductor manufacturing to organize cells of different types to produce a tissue with emergent properties. These efforts have produced human microlivers which model human drug metabolism, drug-induced liver disease, and interaction with human pathogens, thereby establishing high-throughput models that fully replicate the life cycles of hepatitis C and liver-stage human malaria, and are being used for drug testing, discovery, and tissue engineering applications. We are also involved in a multidisciplinary effort to develop nanomaterials as tools for biological studies and as multifunctional agents for cancer therapies. By bridging the unique electromagnetic properties of nanomaterials with advances in bioconjugate chemistry, photonics, and phage display we aim to develop “intelligent” systems for tumor therapy and biomolecular detection. Our interest centers around nanoparticles and nanoporous materials that can be designed to perform complex tasks such as home to a tumor, sense changes in cells and tissues, enhance imaging, recruit complementary nanoparticles and signal pathways, and trigger the release of a targeted, therapeutic payload.
Some of the work being conducted in the Bhatia lab is profiled as part of the current interactive exhibits in the Koch Institute Public Galleries. Watch a web version of the story here.
- A. F. Bagley, R. Scherz-Shouval, P. A. Galie, A. Q. Zhang, J. Wyckoff, L. Whitesell, C. S. Chen, S. Lindquist, and S. N. Bhatia. “Endothelial thermotolerance impairs nanoparticle transport in tumors.” Cancer Res 75.16 (2015): 3255-67.
- V. Ramanan†, A. Shlomai†, D. B. T. Cox†, R. E. Schwartz, E. Michailidis, A. Bhatta, D. A. Scott, F. Zhang‡, C. M. Rice‡, and S. N. Bhatia‡. “CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.” Sci Rep 5 (2015).
- T. Danino†, A. Prindle†, G. A. Kwong, M. Skalak, H. Li, K. Allen, J. Hasty‡, and S. N. Bhatia‡. “Programmable probiotics for detection of cancer in urine.” Science Translational Medicine 7 (2015): 289ra84.
- N. E. Reticker-Flynn and S. N. Bhatia. “Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche.” Cancer Discov 5.2 (2015): 168-81.
- A. Shlomai†, R. E. Schwartz†, V. Ramanan†, A. Bhatta, Y. P. de Jong, S. N. Bhatia‡, and C. M. Rice‡. “Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems.” Proc Natl Acad Sci USA 111.33 (2014): 12193-8.
- S. March, S. Y. Ng, S. Velmurugan, A. Galstian, J. Shan, D. J. Logan, A. E. Carpenter, D. Thomas, B. Kim Lee Sim, M. M. Mota, S. L. Hoffman, and S. N. Bhatia. “A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax.” Cell Host Microbe 14.1 (2013): 104-115.
- J. D. Baranski, R. R. Chaturvedi, K. R. Stevens, J. Eyckmans, B. Carvahlo, R. D. Solorzano, M. T. Yang, J.S. Miller, S. N. Bhatia, and C. S. Chen. “Geometric control of vascular networks to enhance engineered tissue integration and function.” PNAS 110 (2013): 7586-7591.
- J. Shan, R. E. Schwartz, N. T. Ross, D. J. Logan, S. A. Duncan, T. E. North, W. Goessling, A. E. Carpenter, and S. N. Bhatia. “Identification of small molecules for human hepatocyte expansion and iPS differentiation.” Nature Chemical Biology (2013): 514-20.
- G. A. Kwong, G. von Maltzahn, G. Murugappan, O. Abudayyeh, S. Mo, I. A. Papayannopoulos, D. Y. Sverdlov, S. B. Liu, A. D. Warren, Y. Popov, D. Schuppan, and S. N. Bhatia. “Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease.” Nature Biotechnology 31 (2012): 63-70.
A full list of Professor Bhatia’s publications can be found on her website.